Marksans Pharma Ltd.

NSE: MARKSANS | BSE: 524404 | ISIN: INE750C01026 | Industry: Pharmaceuticals
| Mid-range Performer
179.1100 0.74 (0.41%)
NSE Sep 19, 2025 15:31 PM
Volume: 853.4K
 

179.11
0.41%
Dynamic Levels
Marksans R&D; capabilities include dossier development, chemical synthesis, process optimization, formulation development, analytical development and conducting stability studies. The company has a team of over 50 experienced scientists specializing in formulation development and analytical development. The conpany has possessed end-to-end capabilities from Lab scale development to Pilot scale up and from commercializing the product for large...
Number of FII/FPI investors increased from 153 to 159 in Jun 2025 qtr.
More from Marksans Pharma Ltd.
Recommended